1. Comparable Outcomes Between Adolescent/Young Adults and Children With Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience
- Author
-
Yu-Chuan Wen, Pei-Kwei Tsay, Tsung-Yen Chang, Yi-Lun Wang, Shih-Hsiang Chen, Tang-Her Jaing, and Chun-Chu Chang
- Subjects
Adult ,Pediatrics ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,Single Center ,Disease-Free Survival ,Young Adult ,Recurrence ,hemic and lymphatic diseases ,medicine ,Humans ,Young adult ,Child ,Transplantation ,Univariate analysis ,Hematopoietic cell ,business.industry ,Remission Induction ,Hematopoietic Stem Cell Transplantation ,Myeloid leukemia ,Leukemia, Myeloid, Acute ,surgical procedures, operative ,Surgery ,business ,Psychosocial - Abstract
BACKGROUND The cytogenetics of acute myeloid leukemia (AML) increases exponentially with age. Adolescent and young adult (AYA) patients have specific psychosocial and other challenges, influencing their ability to access appropriate treatment. Therefore, in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for AML, inferior outcomes would be observed in AYA patients compared to children. METHODS We defined the age range of AYA patients as 15 to 29 years. Sixty-three patients who underwent allo-HSCT from 1998 to 2020 at Chang Gung Children Hospital were enrolled in this study. Overall survival was the time duration from HSCT to death from any cause. Disease-free survival was the time duration from HSCT to the last follow-up or first event (failure to achieve complete remission, relapse, secondary malignancy, or death from any cause). RESULTS Thirty-seven (59%) patients were
- Published
- 2021